中国生物工程杂志

［1］ Yu I T S, Li W, Wong T W. Effects of age, period and cohort on acute myocardial infarction mortality in Hong Kong. Int J Cardiol, 2004, 97: 63 68. 
［2］ Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta,2003,330: 3155. 
［3］ Lostaoa L, Regidorb E, Aiachc P, et al. Social inequalities in ischaemic heart and cerebrovascular disease mortality in men: Spain and France,1980~1982 and 1988~1990. Soc Sci Med, 2001,52:18791887. 
［4］ Segel G B, Charles W F. Anticoagulant proteins in childhood venous and arterial thrombosis: a review. Blood Cells Mol, Dis,2000, 26(5): 540–560. 
［5］ Yang T Y, Chung K J, Huang T L, et al. Massive pulmonary embolism in a young patient on clozapine therapy. J Emerg Med,2004, 27(1) 2729. 
［6］ Ginsberg J S. Antithrombotic therapy in children. Thromb. Res, 2003,109: 83. 
［7］ Sobol S E, Elden L M, Wetmore R F. Management of lateral sinus thrombosis in children. Otolaryngol. Head Neck Surg, 2004,240. 
［8］ Temple M, Williamsb S, Johna P, et al. Percutaneous treatment of pediatric thrombosis. Eur J Radiol,2005,53:1421. 
［9］ Kobayashi T, Shinohara M, Tomomasa T, et al. Percutaneous hydrodynamic thrombectomy for femoral arterial thrombosis after arterial catheterization. Pediatr Cardiol,2003, 24(4):409411. 
［10］ Rasche H. Haemostasis and thrombosis: an overview. Eur Heart J Suppl,2001, 3 (Supplement Q): Q3–Q7. 
［11］ Klocker J, Perkmann R, KleinWeigel P, et al. Continuous administration of heparin in patients with dee Pvein thrombosis can increase plasma levels of diamine oxidase. Vascul Pharmacol, 2004,40: 293300. 
［12］ Helft G, Worthley S G. Antithrombotic, antiplatelet and fibrinolytic therapy: current management of acute myocardial infarction. Heart Lung Circ,2001,10: 6874. 
［13］ Atkinson R P, DeLemos C. A cute ischemic stroke management. Thromb Res, 2000,98: V97V111. 
［14］ Merlini P A, Cugno M, Rossi M L, et al. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol, 2004,93: 822 825. 
［15］ Sumino H, Ichikawab S, Sawadab Y, et al. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women Thromb Res, 2005,115:359366. 
［16］ Shackelford D P, Lalikos J F. Estrogen replacement therapy and the surgeon. Am J Surg, 2000,179:333336. 
［17］ Mannucci P M. Venous thromboembolism and hormone replacement therapy. J Intern Med, 2001,12:478483. 
［18］ Factor P. Gene therapy for acute diseases. Mol Ther,2001, 4(6):515524. 
［19］ Glickman. 21st century thrombolytic use. J Radiol Nurs, 2005,24 (2):35. 
［20］ Banerjee A, Chisti Y, Banerjee U C. Streptokinase—a clinically useful thrombolytic agent. Biotechnol Adv, 2004,22:287–307. 
［21］ Yilmaz M B, Akin Y, Guray U, et al. Spontaneous rectus muscle hematoma following streptokinase therapy for acute myocardial infarction: a case report. International Int J Cardiol,2002,84:101–103. 
［22］ Uszynski M, Perlik M, Uszynski W, et al. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues Measurements and clinical implications. Eur J Obstet Gynecol Reprod Biol,2004,114:54–58. 
［23］ Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol,2004,25(8): 450455. 
［24］ Kent D M, Vijan S, Hayward R A, et al. Tissue plasminogen activator was costeffective compared to streptokinase in only selected patients with acute myocardial infarction. J Clin Epidemiol, 2004,57:843–852. 
［25］ Rouf S A, MooYoung M Chisti. Tissuetype plasminogen activator: characteristics, applications and production technology. Biotechnol Adv, 1996,14(3): 239266. 
［26］ Wang P, Zhang J, Sun Z, et al. Glycosylation of prourokinase produced by Pichia pastoris impairs enzymatic activity but not secretion. Protein Expr Purif,2000, 20:179–185. 
［27］ Hua Z C, Dong C, Zhu D X. Renaturation of recombinant human prourokinase expressed in Escherichia coli. Biochem. Biophys Res Commun,1996, 220:131–136. 
［28］ Gurewich. Prourokinase mutants. Enzyme Microb Technol, 1996,19:130. 
［29］ Davydov L, Cheng J W M. Tenecteplase: a review. Clin Ther, 2001,23(7):982997. 
［30］ Sanchez E F, Bush L R, Swenson S, et al. Chimeric fibrolase: covalent attachment of an RGDlike peptide to create a potentially more effective thrombolytic agent,1997,87(3):289302. 
［31］ Torchilin V P. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Deliv Rev,1995, 17:75101. 
［32］ Petri T, Langer G, Bringmann P, et al. Production of vampire bat plasmnogen activator DSPA α1 in CHO and insect cells. J Biotechnol,1995,39: 7583. 
［33］ Nakajima N, Sugimoto M, Ishihara K. Earthwormserine protease: characterization, molecular cloning, and application of the catalytic functions. J Mol Catal, B Enzym,2003, 23:191–212. 
［34］ Lahteenmaki K, Kuusela P, Korhonen T K. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev,2001, 25: 531552 . 
［35］ Chisholm J R S, Smith V J. Comparison of antibacterial activity in the hemocytes of different crustacean species. Comp. Biochem Physiol,1995,110A (1):3945. 
［36］ Yokokawa F, Sameshima H, In Y, et al. Total synthesis and conformational studies of ceratospongamide, a bioactive cyclic heptapeptide from marine origin. Tetrahedron ,2002,58:8127–8143. 
［37］ Shahidi F, JanakKamil Y V A. Enzymes from fish and aquatic invertebrates and their application in the food industry. Trends Food Sci Technol,2001,12: 435464. 
［38］ Zhang Z F, Shao M Y, Kang K H, et al. Studies on the tolerating mechanism for sulfide in Urechis unicinctus (Echiura: urechidae): Cytological observation on Urechis unicinctus in different hydrogen sulfide environment. Chin J Oceanol Limnol,2003, 21(1): 8690. 
［39］ Hu R L, Zhang S F, Liang H Y, et al. Codon optimization, expression, and characterization of recombinant lumbrokinase in goat milk. Protein Expr Purif,2004, 37:83–88. 
［40］ Tang Y, Liang D C, Jiang T, et al. Crystal structure of earthworm fibrinolytic enzyme component A: revealing the structural determinants of its dual fibrinolytic activity. J Mol Biol,2002, 321: 5768. 
［41］ Zhao J, Li L, Wu C, et al. Hydrolysis of fibrinogen and plasminogen by immobilized earthworm fibrinolytic enzyme II from Eisenia fetida. Int J Biol Macromol, 2003,32:165–171. 
［42］ Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem, 1976,72:248254. 
［43］ Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys, 1952,40:346351. 
［44］ Mcdonald C E, Chen L L. The Lowry modification of the folin reagent for determination of proteinase activity. Anal Biochem,1965,10: 175177. 
［45］ Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature,1970, 227 :680685. 
［46］ Liang J F, Li Y. Yang Y C. The potential mechanism for the effect of heparin on tissue plasminogen activator–mediated plasminogen activation. Thromb Res, 2000,97:349–358. 
［47］ Khorana A A, Fine R L. Pancreatic cancer and thromboembolic disease. Lancet Oncol,2004,5: 655–663. 
［48］ Kearon C, Gent M. Heparin therapy for dee Pvein thrombosis: from hospital to home. Am J Med,2001,110:501–502. 
［49］ Govindaraju K, Srinivas H. Studies on the effects of enzymatic hydrolysis on functional and physicochemical properties of arachin. LWT,2004,39(2006):54–62. 
［50］ Wu C, Li L, Zhao J, et al. Effect of a 2M on earthworm fibrinolytic enzyme III1 from Lumbricus rubellus. Int J Biol Macromol, 2002,31:7177. 
［51］ Fan Q, Wu C, Li L, et al. Some features of intestinal absorption of intact fibrinolytic enzyme III1 from Lumbricus rubellus. Biochim Biophys Acta,2001,1526:286292. 
［52］ Yang J S, Ru B G. Purification and characterization of an SDSactivated fibrinolytic enzyme from Eisenia fetida. Comp. Biochem Physiol,1997,118B (3): 623631. 
［53］ Wang C, Wang F, Lia M, et al. Structural basis for broad substrate specificity of earthworm fibrinolytic enzyme component A. Biochem Biophys Res Commun, 2004,325:877–882. 
［54］ Wang F, Wang C, Li M, et al. Crystal structure of earthworm fibrinolytic enzyme component B: a novel, glycosylated twochained trypsin. J Mol Biol,2005,348(6):671685. 
［55］ Düsterhft E M, Linssen V A J M, Voragen A G R, et al. Purification, characterization, and properties of two xylanases from Humicola insolens. Enzyme Microb Technol, 1997,20: 437445.